Nucala mepolizumab regulatory update

FDA approved a BLA from GlaxoSmithKline for Nucala mepolizumab as add-on maintenance treatment of severe eosinophilic asthma in patients ages >=12. GSK plans to launch Nucala by year end at a wholesale acquisition cost (WAC) of $2,500 per single-use vial. The drug is administered in a 100 mg dose subcutaneously every 4 weeks. ...